Skip to main content
main-content

Lung cancer: Targeted therapy

Journal articles and book chapters

10-09-2019 | Non-small cell lung cancer | Video | Article

Researcher comment: AMG 510 for KRAS mutation-positive NSCLC

WATCH | Ramaswamy Govindan outlines the key findings of the non-small-cell lung cancer cohort of the phase I trial of the novel KRAS inhibitor AMG 510, and comments on the next steps for the research (5:34).

08-09-2019 | Lung cancer | Video | Article

Expert highlights from WCLC 2019

WATCH | Advisory Board member Ross Camidge shares his top picks of the presentations at the 2019 World Conference on Lung Cancer, including the CASPIAN trial and the updated AMG 510 data (1:51).

01-06-2019 | Lung cancer | ASCO 2019 | Article

Expert highlights: Lung cancer at ASCO 2019

Advisory Board member Ross Camidge comments on his picks for the most exciting lung cancer research being presented at the 2019 ASCO Annual Meeting, including the RELAY trial and the ARROW trial of the RET inhibitor BLU-667 (3:13).

02-04-2019 | Non-small cell lung cancer | Video | Article

Researcher comment: Liquid biopsy noninferior to tissue biopsy for identifying genomic targets in metastatic NSCLC

Researcher Vassiliki Papadimitrakopoulou describes the findings of the prospective NILE study evaluating the clinical utility of genotyping cell-free DNA in patients with a new diagnosis of metastatic non-small-cell lung cancer (3:21).

01-04-2019 | Non-small cell lung cancer | Video | Article

Expert commentary: TATTON trial – Exploring options for EGFR inhibitor-resistant NSCLC

Roy Herbst provides his views on the phase Ib TATTON study that combined osimertinib with either the MET inhibitor savolitinib or the MEK inhibitor selumetinib in the advanced, resistant NSCLC setting (2:53).

01-04-2019 | Non-small cell lung cancer | Video | Article

Researcher comment: TATTON trial of savolitinib plus osimertinib in EGFR-mutated, MET-amplified NSCLC

Advisory board member and study author Lecia Sequist takes us through the findings of the savolitinib plus osimertinib cohort of the phase Ib TATTON trial of advanced non-small-cell cancer patients who have developed resistance to EGFR inhibitor therapy (4:48).

04-02-2019 | Non-small cell lung cancer | Article

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

Camidge DR et al. Nat Rev Clin Oncol 2019; 16(6): 341-355. doi:10.1038/s41571-019-0173-9.

26-11-2018 | EGFR inhibitors | Article

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

Shah KN et al. Nat Med 2019; 25(1): 111-118. doi:10.1038/s41591-018-0264-7

21-10-2018 | Non-small cell lung cancer | Article

Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors

Wrona A et al. Cancer Treat Rev 2018; 71: 59–67. doi:10.1016/j.ctrv.2018.10.011.

14-08-2018 | Non-small cell lung cancer | Article

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

Recondo G et al. Nat Rev Clin Oncol 2018. doi:10.1038/s41571-018-0081-4

23-04-2018 | Non-small cell lung cancer | Article

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall

Leonetti A et al. Cancer Treat Rev 2018; 66: 82-94. doi:10.1016/j.ctrv.2018.04.006

29-03-2018 | Non-small cell lung cancer | Article

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer

Wu YL et al. J Clin Oncol 2018; 36(14):1405-1411. doi:10.1200/JCO.2017.75.5587

24-01-2018 | Non-small cell lung cancer | Article

The biology and management of non-small cell lung cancer

Herbst RS et a. Nature 2018; 553: 446–454. doi:10.1038/nature25183

18-11-2017 | Non-small cell lung cancer | Article

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Soria JC et al. N Engl J Med 2018; 378(2): 113-125. doi:10.1056/NEJMoa1713137

11-09-2017 | Dabrafenib | Article

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

Planchard D et al. Lancet Oncol 2017; 18(10):1307-1316. doi:10.1016/S1470-2045(17)30679-4

Image Credits